These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 10217055)
1. Biological determinants of cancer progression in men with prostate cancer. Stamey TA; McNeal JE; Yemoto CM; Sigal BM; Johnstone IM JAMA; 1999 Apr; 281(15):1395-400. PubMed ID: 10217055 [TBL] [Abstract][Full Text] [Related]
2. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. Noguchi M; Stamey TA; McNeal JE; Yemoto CM J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. Stamey TA; Yemoto CM; McNeal JE; Sigal BM; Johnstone IM J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486 [TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen and the biologic progression of prostate cancer. Kabalin JN; McNeal JE; Johnstone IM; Stamey TA Urology; 1995 Jul; 46(1):65-70. PubMed ID: 7541589 [TBL] [Abstract][Full Text] [Related]
5. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related]
6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488 [TBL] [Abstract][Full Text] [Related]
7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
8. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. Noguchi M; Stamey TA; Neal JE; Yemoto CE J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175 [TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Wheeler TM; Dillioglugil O; Kattan MW; Arakawa A; Soh S; Suyama K; Ohori M; Scardino PT Hum Pathol; 1998 Aug; 29(8):856-62. PubMed ID: 9712429 [TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739 [TBL] [Abstract][Full Text] [Related]
11. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer. Valicenti RK; Chervoneva I; Gomella LG Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249 [TBL] [Abstract][Full Text] [Related]
12. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
13. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850 [TBL] [Abstract][Full Text] [Related]
14. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients. Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855 [TBL] [Abstract][Full Text] [Related]
15. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734 [TBL] [Abstract][Full Text] [Related]
16. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379 [TBL] [Abstract][Full Text] [Related]
17. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
18. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712 [TBL] [Abstract][Full Text] [Related]
19. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720 [TBL] [Abstract][Full Text] [Related]